Jonsson Comprehensive Cancer Center
Quick facts
Phase 3 pipeline
- androgen deprivation therapy
- bortezomib + rituximab · Oncology
Bortezomib inhibits the proteasome to trigger cancer cell death, while rituximab targets CD20 on B cells to enhance immune-mediated tumor destruction. - trastuxumab · Other
Phase 2 pipeline
- Zipalertinib · Other
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: